Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben Tran

Showing results (51-60 of 170) with videos related to

Pageof 17
Sort By:
Plos One|November 27, 2024
An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escapeAngelyn Anton, Ryan Hutchinson, Christopher M Hovens, et al.
Internal Medicine Journal|February 20, 2019
Impact of access to novel therapies on the initial management of castrate-resistant prostate cancer: an Australian multicentre studyEdmond M Kwan, Marie C Semira, Alice R T Bergin, et al.
JCO Global Oncology|March 6, 2026
Real-World Outcomes in Advanced Clear Cell Renal Cell Carcinoma: A Retrospective Analysis Comparing New Zealand and Australian CohortsWilliam Harris, Sarah Shirley, Elizabeth Liow, et al.
Journal for Immunotherapy of Cancer|September 27, 2018
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumorsBen Tran, Richard D Carvajal, Aurelien Marabelle, et al.
Asia-Pacific Journal of Clinical Oncology|January 11, 2018
Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancerAnis A Hamid, Kaspar Willson, Andrew D Vincent, et al.
Asia-Pacific Journal of Clinical Oncology|June 26, 2024
Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012-2022Nadia Hitchen, Adel Shahnam, Sathya Manoharan, et al.
Basic and Clinical Andrology|September 2, 2024
Association between low total serum testosterone and body mass index in Australian survivors of testicular cancer: a retrospective analysisGrace Y Kim, Ciara Conduit, Sophie O'Haire, et al.
Cell Reports. Medicine|October 18, 2023
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumorsSophia Frentzas, Hui K Gan, Rasha Cosman, et al.
BJU International|July 25, 2015
Patterns of care for metastatic renal cell carcinoma in AustraliaDaphne Day, Yada Kanjanapan, Edmond Kwan, et al.
Investigational New Drugs|May 17, 2018
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancersAflah Roohullah, Adam Cooper, Anna J Lomax, et al.
Pageof 17

Showing results (51-60 of 170) with videos related to

Sort By:
Pageof 17
Plos One|November 27, 2024
An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escapeAngelyn Anton, Ryan Hutchinson, Christopher M Hovens, et al.
Internal Medicine Journal|February 20, 2019
Impact of access to novel therapies on the initial management of castrate-resistant prostate cancer: an Australian multicentre studyEdmond M Kwan, Marie C Semira, Alice R T Bergin, et al.
JCO Global Oncology|March 6, 2026
Real-World Outcomes in Advanced Clear Cell Renal Cell Carcinoma: A Retrospective Analysis Comparing New Zealand and Australian CohortsWilliam Harris, Sarah Shirley, Elizabeth Liow, et al.
Journal for Immunotherapy of Cancer|September 27, 2018
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumorsBen Tran, Richard D Carvajal, Aurelien Marabelle, et al.
Asia-Pacific Journal of Clinical Oncology|January 11, 2018
Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancerAnis A Hamid, Kaspar Willson, Andrew D Vincent, et al.
Asia-Pacific Journal of Clinical Oncology|June 26, 2024
Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012-2022Nadia Hitchen, Adel Shahnam, Sathya Manoharan, et al.
Basic and Clinical Andrology|September 2, 2024
Association between low total serum testosterone and body mass index in Australian survivors of testicular cancer: a retrospective analysisGrace Y Kim, Ciara Conduit, Sophie O'Haire, et al.
Cell Reports. Medicine|October 18, 2023
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumorsSophia Frentzas, Hui K Gan, Rasha Cosman, et al.
BJU International|July 25, 2015
Patterns of care for metastatic renal cell carcinoma in AustraliaDaphne Day, Yada Kanjanapan, Edmond Kwan, et al.
Investigational New Drugs|May 17, 2018
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancersAflah Roohullah, Adam Cooper, Anna J Lomax, et al.
Pageof 17